Adalimumab [Humira]

Not Applicable

01/09/2020 Adalimumab for treating inflammatory conditions

The Ministry of Health’s Drug Advisory Committee has recommended:

Adalimumab biosimilar (Amgevita) 20 mg/0.4 ml prefilled syringe and 40 mg/0.8 ml prefilled autoinjector and syringe for treating the following inflammatory conditions in line with its registered indications in Singapore:

• Adults with moderately to severely active rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, chronic plaque psoriasis, ulcerative colitis, Crohn’s disease or hidradenitis suppurativa;

• Adults with non-infectious intermediate, posterior and panuveitis;

• Children aged 2 years or older with chronic non-infectious anterior uveitis or polyarticular juvenile idiopathic arthritis;

• Children aged 4 years or older with severe chronic plaque psoriasis;

• Children aged 6 years or older with moderately to severely active Crohn’s disease or enthesitis-related arthritis; and

• Children aged 12 years or older with moderate to severe hidradenitis suppurativa;

The removal of adalimumab reference biologic (Humira) 40 mg/0.8 ml prefilled autoinjector from the Medication Assistance Fund (MAF) for all indications; and

Not to list new formulations of Humira (20 mg/0.2 ml or 40 mg/0.4 ml prefilled syringe and pen) on SDL or MAF in view of unfavourable cost effectiveness compared with Amgevita at the price proposed by the manufacturer.

Subsidy status

[R] Adalimumab biosimilar (Amgevita) 20 mg/0.4 ml prefilled syringe and 40 mg/0.8 ml prefilled autoinjector and syringe are recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indications from 1 September 2020. The MAF listing of Humira will cease on 1 March 2021.

[NR] SDL subsidy does not apply to any formulations or strengths of Humira.

View legend